Skip to main content

Near Death, Interleukin Genetics Secures $500K in New Financing

NEW YORK, Jan. 30 - Interleukin Genetics today said it has secured $500,000 in interim financing, extending its lifespan through the end of February.

 

The firm said Pyxis Innovations, a sister company to consumer products giant Amway, had bought a fourth $500,000 promissory note. Three others were sold in the fall of last year. Each accrues interest at the rate of 15 percent annually, and will mature Dec. 31.

 

Interleukin Genetics has been struggling to bring in enough cash to stay afloat. The company reported $80,000 in revenues and a $1.4 million net loss for the third quarter of 2002, and held only $508,000 in cash and cash equivalents at the end of September 2002. It was delisted from the Nasdaq in December 2002.

 

Pyxis Innovations, a division of Alticor, develops nutrition, beauty and wellness products for Alticor, the parent company of Amway. Interleukin Genetics, based in Waltham, Mass., is focused on developing therapeutics, diagnostics and nutriceutical products for inflammation.

 

Click here for more information.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.